![Latest pharma industry updates by Nicolas Schmitz](https://oncodaily.com/pub/uploads/2024/01/download-19.jpg)
Photo of Nicolas Schmitz taken from LinkedIn
Jan 12, 2024, 17:07
Latest pharma industry updates by Nicolas Schmitz
Nicolas Schmitz,
“Latest pharma industry updates:
- Pharma stocks globally faced a challenging 2023, with only anti-obesity Eli Lilly and Company and Novo Nordisk shining.
- Goldman Sachs closes a $650M fund for life sciences investments, one of the largest first-time private funds in the sector.
- Longboard Pharmaceuticals shares surge 316% after promising data from bexicaserin study for developmental and epileptic encephalopathies.
- Esperion amends collaboration with Daiichi Sankyo, Inc. resolving disputes with a $125 million agreement.
- Roche partners with Remix Therapeutics, exploring new RNA-targeting drugs, the third such deal following Arrakis and Ribometrix.
- Pfizer secures Canadian approval for its first gene therapy, Beqvez, for hemophilia B.
- Eli Lilly and Company launches “LillyDirect,” an online service in the U.S. for obesity, migraine, and diabetes treatments, including delivery and telehealth support.
- Dermata Therapeutics, Inc. shares rise 113% after securing a new patent in Japan for DMT410 in hyperhidrosis treatment.
- Novo Nordisk announces research partnerships with Omega Therapeutics and Cellarity for obesity and NASH treatments.
- Boehringer Ingelheim collaborates with Ribocure Pharmaceuticals AB to develop RNAi-based liver disease treatments, including NASH.
- Merck CEO Robert Davis highlights GLP-1 treatments with benefits beyond weight loss, citing efinopegdutide’s potential in NASH.
- Evotec CEO Werner Lanthaler resigns after a challenging year, leading to a 20% drop in company’s stock.
- Innate Pharma’s lacutamab trial resumes post-FDA investigation into a patient’s death.
- Allogene Therapeutics plans strategic shift to improve CAR-T therapy use in earlier treatment stages.
- Lykos Therapeutics (formerly MAPS PBC) raises over $100M for MDMA-based PTSD therapy, eyeing FDA approval.
- Intellia Therapeutics, Inc. announces layoffs and research cuts, focusing on priority drug programs.
- Roche signs $50M ADC deal with a Chinese biotech, continuing its expansion in the field.
- Roche secures a $66M deal with MOMA Therapeutics, the third significant pact of the week
- Nemaura Pharma Limited opts for delisting from Nasdaq, moving to OTC Markets, with shares falling 32%.”
Source: Nicolas Schmitz/LinkedIn
Allogene Therapeutics
Arrakis
Beqvez
bexicaserin
Boehringer Ingelheim
cancer
Cellarity
Daiichi Sankyo
Dermata Therapeutics
DMT410
efinopegdutide
Eli Lilly and Company
Esperion
Goldman Sachs
Inc
Innate Pharma
Intellia Therapeutics
KBI Biopharma
LillyDirect
Longboard Pharmaceuticals
Lykos Therapeutics
Nemaura Pharma Limited
Nicolas Schmitz
Novo Nordisk
Omega Therapeutics
OncoDaily
Oncology
pfizer
Remix Therapeutics
Ribocure Pharmaceuticals AB
Ribometrix
Robert Davis
Roche
Werner Lanthaler
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2024, 18:11